SAPPHIRE BIOTECH, INC.

Biotech · Acquired

Small molecule inhibitors targeting the QSOX1 enzyme for cancer treatment

Grants
$396K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
23
0 granted · 23 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Identification of Small Molecule Inhibitors of QSOX1$395,880
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1635Find Genomics Inc.——
1636Amplifier Therapeutics——
1637Rapt Therapeutics—$303M
1638SAPPHIRE BIOTECH, INC.——
1639Atalanta Therapeutics——
1640Aera Therapeutics——
1641LIGANDOMICSRX, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 23
  • Molecules, And Related Assays, Test Kits And Methodsapplication
  • Neutralizing Antibody Testing And Treatmentapplication
  • Assay For Neutralizing Antibody Testing And Treatmentapplication
  • Systems And Methods For Rapid Diagnostic For Various Cancersapplication
  • Tear Sample Collectors, Systems And Methodsapplication
  • Tests For Human Monomeric Lacritinapplication
  • Tests For Detection Of Neutralizing And Non-neutralizing Antibodies And Related Methodsapplication
  • Development Of The Engender SARS-COV-2 Recombinant Protein Variantsapplication
  • Rapid Point of Care and Clinical Diagnostic Tests to Measure Levels of Neutralizing Antibodies to COVID19application
  • Rapid LFA Diagnostic Test to Measure Levels of Neutralizing Antibodies to SARS-CoV-2 from Whole Bloodapplication
  • Rapid LFA Diagnostic Test to Measure Levels of Neutralizing Antibodies to SARS-CoV-2 from Whole Bloodapplication
  • Rapid LFA Diagnostic Test to Measure Levels of Neutralizing Antibodies to SARS-CoV-2 from Whole Bloodapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.